CD8A and neoplasm: This inhibition was associated with a decrease in target cell killing by CD8+ TIL from anti-PD-1 plus anti-CD103-treated B16F10E-KO as compared to CD8+ TIL from anti-PD-1 plus isotype-treated tumours (Fig. 6b).